| Literature DB >> 29869936 |
Lili Xiang1, Ying Li2,3, Xu Deng4, Djuro Kosanovic5, Ralph Theo Schermuly5, Xiaohui Li1,3.
Abstract
Pulmonary arterial hypertension (PAH) is a severe disease characterized by progressive remodeling of distal pulmonary arteries and persistent elevation of pulmonary vascular resistance (PVR), which leads to right ventricular dysfunction, heart failure, and eventually death. Although treatment responsiveness for this disease is improving, it continues to be a life-threatening condition. With the clinical efficacy of natural plant products being fully confirmed by years of practice, more and more recognition and attention have been obtained from the international pharmaceutical industry. Moreover, studies over the past decades have demonstrated that drugs derived from natural plants show unique advantages and broad application prospects in PAH treatment, not to mention the historical application of Chinese traditional medicine in cardiopulmonary diseases. In this review, we focus on summarizing natural plant compounds with therapeutic properties in PAH, according to the extracts, fractions, and pure compounds from plants into categories, hoping it to be helpful for basic research and clinical application.Entities:
Keywords: natural products; pulmonary arterial hypertension; pulmonary vascular resistance; traditional Chinese medicine; treatment
Year: 2018 PMID: 29869936 PMCID: PMC6055327 DOI: 10.1177/2045894018784033
Source DB: PubMed Journal: Pulm Circ ISSN: 2045-8932 Impact factor: 3.017
Natural plants for any vascular disease.
| Vascular disease | Natural plants | Efficacy | Reference |
|---|---|---|---|
| Atherosclerosis | Ginkgo biloba leaf | • Reduce atherosclerotic nanoplaque formation and size, suppress atherosclerotic lesion development • Reduce intima-media ratio, decrease proliferation and migration of VSMCs, and induce greater apoptosis • Improve glucose homeostasis and circulating adiponectin levels, attenuate the expression of connexin 43 protein and the concentrations of plasma Homo sapiens C-reactive protein |
[ |
| Salvia miltiorrhiza Bunge | • Inhibit atherosclerotic lesion formation in aorta • Lower cholesterol and inhibit low density lipoprotein oxidative modification • Downregulate protein expression and activities of matrix metalloproteinase-2 and matrix metalloproteinase-9 through inhibiting nicotinamide adenine dinucleotide phosphate oxidase 4-mediated reactive oxygen species generation |
[ | |
| Green tea | • Protect apolipoprotein E−/− mice from atherosclerosis through the Jagged 1/Notch pathway • Attenuates atherosclerotic lesion formation and development through decreasing macrophage cholesterol content and MCP-1 expression in macrophages • Reduce total cholesterol, triglycerides, low-density and very low-density lipoprotein cholesterol fractions, and increase high-density lipoprotein |
[ | |
| Astragalus membranaceus | • Alleviate the extent of atherosclerosis in aorta of apolipoprotein E−/− mice • Suppress the progression of atherosclerotic lesions and the inflammatory reaction • Reduce plasma levels of total cholesterol and low-density lipoprotein cholesterol, increase high density lipoprotein cholesterol levels, and reduce the aortic fatty streak area |
[ | |
| Thrombus and platelet aggregation | Ginkgo biloba leaf | • Inhibit platelet aggregation induced by oxidative stress, platelet activation factor, or collagen • Reduce the plasma levels of thromboxane B2 and prostacyclin metabolites • Inhibit the production of cyclooxygenase-1-mediated thromboxaneA2 in platelets and cyclooxygenase-2-mediated prostaglandin I2 in endothelial cells non-selectively |
[ |
| Salvia miltiorrhiza Bunge | • Inhibits thrombosis formation, platelet aggregation • Inhibits platelet adhesion to immobilized collagen by interfering with the collagen receptor α2β1 • Suppress [Ca2+]i mobilization and arachidonic acid liberation |
[ | |
| Uncaria rhynchophylla | • Inhibit platelet aggregation and antithrombotic • Reduce the thromboxane B2 generation in platelet rich plasma induced by collagen • Suppress the formation of malondialdehyde in platelet suspension stimulated by thrombin and inhibit the release of platelet factor 4 |
[ | |
| Anemarrhena asphodeloides | • Inhibit platelet aggregation, blood coagulation, as well as the formation of a thrombus • Delay the activated time of thromboplastin • Antiplatelet and anticoagulation |
[ | |
| Panax notoginseng | • Inhibit platelet aggregation and plasma coagulation • Suppress thrombin-induced platelet superficial activation and adhesion in vitro and improve hypercoagulable state in vivo • Over-express peroxisome proliferator-activated receptor γ protein and mRNA and upregulate phosphatidylinositol 3 kinase/protein kinase B through endothelial NOS pathway in platelet |
[ | |
| Hypertension | Ginkgo biloba leaf | • Protect against hypertension with hypercholesterolemia-induced renal injury • Reduce vasospasm and increase relaxation • Suppress renal oxidative stress, nitrosative stress, and inflammation |
[ |
| Salvia miltiorrhiza Bunge | • Lower arterial blood pressure under basal conditions in spontaneously hypertensive rat models and relax coronary arteries in a cumulative dose-dependent manner • Decreased the average blood flow velocity in liver in ET-1 induced portal hypertension • Improve cardiac function and reduce arterial blood pressure partially via inhibiting nicotinamide adenine dinucleotide phosphate oxidase and activating the nitric oxide signaling pathway |
[ | |
| Uncaria rhynchophylla | • Anti-hypertensive, anti-arrhythmic, anti-thrombotic and inhibit platelet aggregation • Lower the blood pressure, improve the structural integrity of vascular endothelium • Decrease the expression of intercellular adhesion molecule 1 and selectin P, block the release of calcium from intracellular stores |
[ | |
| Ligusticum wallichii Rhizome | • Elicit an effect on vasorelaxation in isolated rat aortas and anti-hypertension in spontaneously hypertensive rat • Reduce portal pressure in portal hypertensive rats |
[ | |
| Ischemia-reperfusion injury | Ginkgo biloba leaf | • Protect against myocardium ischemic/reperfusion injury by decreasing oxidative stress, repressing inflammatory cascade in vivo, and inhibiting toll-like receptor 4/nuclear factor kappa B pathway in rat model • Suppress renal epithelial tubular cell apoptosis • Decrease NO production by inhibiting gene and protein expression and enzymatic activity of inducible NOS |
[ |
| Salvia miltiorrhiza Bunge | • Prevent cardiac ischemic/reperfusion injury and improve cardiac function in a rat model of hypertrophy • Protect against neonatal hypoxia-ischemia brain injury in vivo by an increase in the ratio of Bcl-2 to Bax expression • Protect the mitochondrial membrane from the ischemia-reperfusion injury and lipid peroxidation through an electron transfer reaction in mitochondria against forming reactive oxygen radicals |
[ | |
| Uncaria rhynchophylla | • Protect against cerebral ischemia/reperfusion damage • Significantly reduce infarct volume and improve neurological function after ischemic brain injury through the inhibition of lipopolysaccharide-stimulated production of pro-inflammatory cytokines • Reduce the lipid peroxidation injury of brain cells through inhibiting the NOS activity and increasing the superoxide dismutase activity |
[ | |
| Ligusticum wallichii Rhizome | • Suppress ischemia-induced ventricular arrhythmias and reduce the infarct size resulting from ischemia/reperfusion injury • Enhance myocardial antioxidant status through induction of heme oxygenase-1 and inhibition of neutrophil and improve the immunity profile in ischemic-reperfusion rats • Protect cells against glutamate-induced apoptosis via the inhibition of oxidative stress and a change in the levels of apoptosis-related proteins, Bcl-2 and Bax • Reduce cerebral ischemia/reperfusion-induced inflammatory cell activation and pro-inflammatory mediator production |
[ | |
| Anemarrhena asphodeloides | • Decrease total infarct volume and edema in the ipsilateral hemispheres of ischemia-reperfusion rats • Inhibit increased neutrophil infiltration of ischemic brain tissue • Reduce myeloperoxidase positive cells in striatal and cortical areas |
[ |
Bcl-2, B cell leukemia/lymphoma 2; Bax, Bcl-2-associated protein x; ET-1, endothelin-1; NO, nitric oxide; NOS, nitric oxide synthase.
Natural plant products for possible PAH treatment.
| Category | Natural products | Origin | Efficacy | Mechanism | Subjects | Reference |
|---|---|---|---|---|---|---|
| Alkaloids | Ligustrazine | Decrease plasma ET-1 level, reduce mPAP and PVR | Dog |
[ | ||
| Enhance the synthesis and release of NO and suppress those of ET-1; decrease mPAP, internal diameter of right ventricle, and outflow of right ventricle | Human |
[ | ||||
| Attenuate the plate aggregation, reduce thrombus formation and blood viscosity, accelerate blood flow restoration | Rat |
[ | ||||
| Inhibit the platelet aggregation formation and thrombus | Human |
[ | ||||
| Inhibit platelet activation | Inhibit the intracellular calcium ion concentration | Rat |
[ | |||
| Tetrandrine | Inhibit PASMCs proliferation, improve endothelial function; reduce mPAP and RVH index; reverse pulmonary vascular remodeling and attenuate oxidation in lung | Adjust the imbalance of the NO signaling pathway and change the expression of inducible NOS and cyclic guanosine monophosphate-dependent protein kinase-1. | Rat |
[ | ||
| Inhibit the activity of serum angiotensin enzyme, decrease the amount of angiotensin I converted to angiotensin II, suppress the proliferation of medullar collagen and PASMCs in pulmonary acinar artery, reduce pulmonary vasoconstriction and lower PH |
[ | |||||
| TET is a calcium antagonist that blocks the influx of calcium from vascular smooth muscle, relaxes vascular smooth muscle; it also decreases the content of prostaglandin F2 in the lung, so as to reduce the contractility of the pulmonary vasculature and thus reduce the PH |
[ | |||||
| Flavonoids | Ginkgo biloba extracts |
| Relieve RVH and reduce chronic hypoxic PH | Attenuate the function of PKC signal channel | Rat |
[ |
| Antagonize platelet activating factor, angiotensin and reduce blood viscosity |
[ | |||||
| Puerarin |
| Inhibit pulmonary vascular remodeling, RVH, and PH | Inhibit the deposition of collagen | Rat |
[ | |
| Reduce mitochondrial membrane potential, cytochrome C release and caspase-9 activation, inhibit cell growth and apoptosis | Downregulated the expression of elongation factor 2 | Rat |
[ | |||
| Downregulate Bcl-2 and upregulate Bax. | Human |
[ | ||||
| Glycosides | Salidroside |
| Rhodiola has been shown to be beneficial in high-altitude PH |
[ | ||
| Reduce mPAP and RVH, attenuate remodeling of pulmonary arterial | Lower VEGF expression | Rat |
[ | |||
| Inhibit transforming growth factor beta expression and attenuate PH |
[ | |||||
| Reverse hypoxia-induced inhibition of Cytochrome C release from mitochondria into cytoplasm, enhance the cleavage of caspase 3, and increase adenosine A2a receptor expression | Enhance adenosine A2a receptor related mitochondria-dependent apoptosis | Mice |
[ | |||
| Exert protective effect against PAH via rebalancing cell proliferation and mitochondria-dependent apoptosis of PASMCs | Decrease the expression of cyclin D1 and increase the accumulation of P27 by blocking the protein kinase B/glycogen synthase kinase 3 beta signaling pathway | Rat PASMCs |
[ | |||
| Inhibit DNA synthesis and proliferation of rabbit PASMCs, reduce pulmonary vascular remodeling | Inhibit upregulation of Ca2+ concentration induced by hypoxia in PASMCs | Rabbit |
[ | |||
| Reverse hypoxia-induced PASMC proliferation and apoptosis resistance, attenuate chronic hypoxia-induced RVH and pulmonary artery remodeling | Inhibit PASMC proliferation via AMPKα-p53-p27/p21 pathway and reverse apoptosis resistance via AMPKα1-P53-Bax/Bcl-2-caspase 9-caspase 3 pathway | Rat |
[ | |||
| Polydatin | Improve fibrinolytic activity, increase cardiac output, and reduce PAP | Pig |
[ | |||
| Regulate NO, angiotensin II, ET contents in the serum and lung samples, reverse remodeling, and attenuate hypoxic PH | Attenuate the phosphorylation of PKCα and δ induced by H2O2; meanwhile, increase the phosphorylation of PKCɛ which has antioxidant effects | Rat |
[ | |||
| Icariin |
| Markedly shorten right ventricle systolic duration and notably prolong diastolic duration and attenuate the abnormal hemodynamics of pulmonary artery and right ventricle | Rat |
[ | ||
| Attenuate mPAP, RVH index and pulmonary artery remodeling | Decrease the contents of serum angiotensin II, ET, prostaglandin F2, thromboxane A2, and prostaglandin I2, and inhibit the gene expression of angiotensin I converting enzyme, cytochrome c oxidase subunit II, and thromboxane A synthase |
[ | ||||
| Upregulate the expression of endothelial NOS and downregulate the expression of 5-type phosphodiesterase inhibitors, increase the content of NO and cyclic guanosine monophosphate in lung tissue and ameliorate PH | Protect against MCT-induced PAH in rats through increase of NO/cyclic guanosine monophosphate signaling pathway |
[ | ||||
| Diterpenoids | Tanshinone IIA | Recover acute hypoxia-induced downregulation of Ikv currents and upregulate the mRNA and protein expression of Kv1.5 and Kv2.1 in PASMCs, reduce right ventricular systolic pressure and RVH, and restrain pulmonary wall remodeling | Reverse the Ikv currents through modulate the expression of Kv channels in pulmonary arterioles | Rat |
[ | |
| Inhibit cell proliferation | Arrest cells in G1/G0-phase by slowing down the hypoxia-induced degradation of p27 via serine threonine kinase 1/S-phase kinase associated protein 2-associated pathway |
[ | ||||
| Sodium Tanshinone IIA sulfonate | Decrease right ventricular systolic PAP and RVH, attenuate medial wall thickening, PVR and remodeling | Inhibit increase of transient receptor potential superfamily members 1,6 and decrease SOCE through reducing the numbers or activity of SOCC and basal [Ca2+] |
[ | |||
| Stimulate Kv2.1 expression through the regulation of intracellular Ca2+ homeostasis |
[ | |||||
| Reduce pulmonary artery systolic pressure and Borg dyspnea score, improve exercise capacity, and decrease WHO FC of PH from III or IV down to II | Human |
[ | ||||
| Triptolide |
| Promote the regression of pulmonary artery neointimal formation, attenuate the development of RVH, pulmonary remodeling, and PH | Antiproliferation and anti-inflammatory effects or enhancement of apoptosis in PAECs | Rat |
[ | |
| Inhibit the activity of matrix metalloproteinases |
[ | |||||
| Effect the balance of matrix metalloproteinase 9/tissue inhibitor of metalloproteinase 1 |
[ | |||||
| Pyanocoumarins | Praeruptorin A | Inhibit PASMC proliferation and attenuate PH | Inhibit chronically hypoxic enhancement of basal [Ca2+]i and SOCE | Rat |
[ | |
| Inhibit hypoxia caused Kv1.5 and Kv2.1 mRNA expression down, maintain cell membrane potential balance |
[ | |||||
| Stilbenes | Resveratrol | Prevent hypoxia-induced human PASMC proliferation, attenuate RVH | Induct the serine threonine kinase 1-dependent inhibition of arginase II. | Human |
[ | |
| Attenuate oxidative stress and inhibit inflammatory reaction, improve the function of PAECs, reverse the right ventricle and pulmonary artery reconstruction | Rat |
[ | ||||
| Reduce mPAP and PH | Suppress the expression of MCP-1 and p- p38-mitogen-activated protein kinase expression | Rat |
[ | |||
| Others | Semen lepidii |
| Enhance myocardial contractility, reduce PH | Rabbit |
[ | |
| Increase partial pressure of O2 and decrease partial pressure of CO2, reduce mPAP and PVR | Human |
[ | ||||
| Reduce right ventricular systolic and diastolic blood pressure and mPAP | Rat |
[ | ||||
|
[ | ||||||
| Radix Astragali | Inhibit proliferation of adventitial cells, hypertrophic of tunica media, muscularization of non-muscular arteries and the structural remodeling of intra-acinar pulmonary arteries and PH | Preserve the endothelial cells, dilate the pulmonary circulation, and improve hemodynamic condition | Rat |
[ | ||
| Preserve intra-acinar pulmonary arteries wall cells proliferation, dilate pulmonary artery, inhibit intra-acinar pulmonary arteries remodeling, and improve PH |
[ | |||||
| Regulate the concentration of ET-1and NO in pulmonary tissue, reverse the reconstruction of pulmonary vessels partially |
[ | |||||
| Decrease the concentration of thromboxane A2 and reverse the remodeling of pulmonary artery partly |
[ | |||||
| Regulate the concentration of superoxide dismutase and oxygen free radicals in pulmonary tissue | Protect pulmonary vascular from hypoxia by anti-oxidant effects |
[ | ||||
| Eliminate oxygen free radicals and reduce blood viscosity | Human |
[ |
AMPK, adenosine monophosphate-activated protein kinase; Bcl-2, B cell leukemia/lymphoma 2; Bax, Bcl-2-associated protein x; ET-1, endothelin-1; FC, functional class; Kv, voltage-gated K+; MCT, monocrotaline; mPAP, mean pulmonary arterial pressure; NO, nitric oxide; PAEC, pulmonary arterial endothelial cell; PAH, pulmonary arterial hypertension; PH, pulmonary hypertension; PASMC, pulmonary artery smooth muscle cell; PKC, protein kinase C; PVR, pulmonary vascular resistance; RVH, right ventricular hypertrophy; SOCC, store-operated calcium channel; SOCE, SOCC-mediated store-operated Ca2+ entry; TET, Tetrandrine; WHO, World Health Organization.